Skip to main content
Clinical Trials/ISRCTN34410935
ISRCTN34410935
Completed
未知

A pilot study to examine the safety and efficacy of intravitreal ranubizumab/dexamethasone administration and oral minocycline in addition to Visudyne (verteporfin) photodynamic therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: an open-label trial

King's College Hospital NHS Foundation Trust (UK)0 sites20 target enrollmentMay 30, 2008

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
King's College Hospital NHS Foundation Trust (UK)
Enrollment
20
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 30, 2008
End Date
TBD
Last Updated
8 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
King's College Hospital NHS Foundation Trust (UK)

Eligibility Criteria

Inclusion Criteria

  • 1\. The patient must be willing to give written informed consent
  • 2\. The patient must be able to undertake the necessary tests and treatment and be willing to be followed up
  • 3\. Age 50 years or older
  • 4\. Clinical diagnosis of AMD
  • 5\. Subfoveal CNV confirmed by fluorescein angiography
  • 6\. Logarithmic minimal angle of resolution (LogMAR) best corrected visual acuity of 24 \- 73 letters on early treatment diabetic retinopathy study (ETDRS) chart

Exclusion Criteria

  • 1\. Inability to understand or sign consent form
  • 2\. The patient has a current medical condition or history of a medical condition that would be likely to preclude scheduled study visits such as unstable angina, dialysis, and active cancer
  • 3\. Patient has a current ophthalmic condition or history of an ophthalmic condition that might compromise the assessment of the treatment such as diabetic retinopathy, uveitis, amblyopia, ischaemic optic neuropathy
  • 4\. Signs of a myopic retina or refraction of greater than \-8 dioptres in their current or any previous glasses prescription
  • 5\. Signs of other retinal conditions that may have caused the CNV such as angioid streaks, choroidal rupture, and old chorio\-retinitis
  • 6\. Open angle glaucoma
  • 7\. At increased risk of developing glaucoma such as having pigment dispersion syndrome or pseudoexfoliation
  • 8\. Unable to have a good quality fluorescein angiogram taken, e.g., due to head tremor or media opacity
  • 9\. Known hypersensitivity to fluorescein or any of the study medications
  • 10\. Previous treatment for a retinal detachment

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
A pilot study to examine the safety and efficacy of posterior juxta-scleral (80 mg) triamcinolone acetonide, administration, in addition to Visudyne (verteporfin) photodynamic therapy for predominantly classic choroidal neovascularisation secondary to age-related macular degeneration: an open-label, randomised, active controlled trial
ISRCTN33957677King's College Hospital (UK)80
Active, not recruiting
Not Applicable
A pilot study to examine the efficacy and safety of escitalopram in doses up to 50 mg for the treatment of patients with Major Depressive Disorder (MDD). - Resistant Depression StudyMajor Depressive DisorderMedDRA version: 9.1Level: LLTClassification code 10025453Term: Major depressive disorder NOS
EUCTR2008-003359-58-GBCPS Research60
Completed
Phase 2
A pilot study to explore the efficacy and safety of jam oral immunotherapy with hypoallergenized cow's milk for children with cow's milk allergyfood allergy (cow&#39s milk)
JPRN-UMIN000018372ational Center for Child Health and Development10
Recruiting
Phase 2
Pilot cml autograft/glivec (STI571)/Intron A trialAdvanced phase chronic myeloid leukaemiaPh-positive acute lymphoblastic leukemiaCancer - Leukaemia - Acute leukaemia
ACTRN12605000071628Australasian Leukaemia and Lymphoma Group48
Completed
Not Applicable
Safety and efficacy of Transcend CyPass glaucoma implant in open angle glaucoma patients who have failed medical treatmentPrimary open angle glaucomaEye DiseasesGlaucoma
ISRCTN23263504Transcend Medical, Inc.™ (USA)20